Virtual monitoring by mobile phone ensures TB patients complete medication

13 September 2013

Sending videos by mobile phone is an effective technique to ensure TB patients take their prescribed medication and complete their course of treatment.

The study by researchers from the Royal Free London NHS Foundation Trust suggests it is an effective alternative method to directly observed treatment (DOT), which is recommended by the World Health Organization. Directly observing treatments is often time consuming for a patient and is resource intensive for healthcare professionals in outreach projects that seek to help people who may not wish to visit a clinic.

The virtually observed treatment (VOT) method instead requires people to send a short video of them taking their medication, to their healthcare provider using a mobile phone. After an initial visit to the clinic, this can be completed remotely, with any issues being followed up when required.

In a pilot project the researchers were able to observe 86% of scheduled doses and concluded that this was a feasible method of monitoring TB treatment programmes in people able to use VOT.

Lead author, Sara Hemming, said: “These preliminary findings suggest that telemedicine can help us overcome the difficulties we’ve seen in directly monitoring patients taking their medicine. Some people are unable or unwilling to visit clinics for a variety of reasons, but by enabling healthcare professionals to virtually monitor patients, we can still ensure effective medication use without the need for a one-to-one session.

“This has the potential to not only reach people who are otherwise unengaged, but also reduce costs and resources. A larger trial comparing the two techniques is needed to ensure the safety and reliability of this technique, and also determine who benefits most from this approach.”

European Respiratory Society President, Professor Francesco Blasi, said: “The European Lung White Book, which is launched this week, calls on countries with high rates of TB, to set up strategies to manage the large numbers of people with drug-susceptible and multidrug-resistant-TB (MDR-TB). This study shows one way that could improve the effectiveness of treatments for people who are particularly hard-to-reach. The outcomes of this pilot study are positive and I look forward to seeing the results of a larger trial.”

The research was presented at the European Respiratory Society (ERS) Annual Congress.

Further information

See MTB Europe news: Lung diseases cost EU nations €400bn/yr for details of The European Lung White Book.